TNFα is an important survival and growth signal for melanoma.

Slides:

Advertisements

Similar presentations

CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.

Advertisements

Yongping Shao, Kaitlyn Le, Hanyin Cheng, Andrew E. Aplin

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

A FOXO3a-BIM cascade mediates sensitivity to PARP and MEK inhibition

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

Proline supplementation during P5CS protein knockdown suppressed GCN2 activation. Proline supplementation during P5CS protein knockdown suppressed GCN2.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Tumor development of poorly immunogenic LLC and B16F10 cells modified to produce GM-CSF was markedly inhibited. Tumor development of poorly immunogenic.

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia by Parvathi Ranganathan, Xueyan Yu, Caroline Na, Ramasamy Santhanam, Sharon Shacham,

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.

NF1 downregulation activates MAPK pathway signaling.

Volume 29, Issue 3, Pages (March 2016)

Regulated P124SMEK1 expression cannot alter p-ERK levels or sensitivity to BRAF or MEK inhibition in V600EBRAF melanoma cell lines. Regulated P124SMEK1.

NrasG12D induces CNS tumors in mice.

EGFR is intrinsically active in FGFR3-activated cell lines with combination efficacy from targeting both EGFR and FGFR3. EGFR is intrinsically active in.

Imipramine and promethazine induce the apoptotic cell death of SCLC cells through activation of caspase-3. Imipramine and promethazine induce the apoptotic.

A genome-wide RNAi pooled screen identifies NF1 as a key determinant of RAF inhibitor sensitivity in melanoma cells. A genome-wide RNAi pooled screen identifies.

AMPK induces VEGF-A production by upregulating ERK signaling.

A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.

Fig. 1 LB100 and LB102 specifically inhibit PP2A phosphatase activity and the growth of BCR-ABL+ cells. LB100 and LB102 specifically inhibit PP2A phosphatase.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

ONC201 activates the ATF4 pathway through the eIF2α kinases HRI and PKR. ONC201 activates the ATF4 pathway through the eIF2α kinases HRI and PKR. (A) Western.

eIF5A-PEAK1 signaling regulates KRAS protein expression.

JAK3A572V mutation causes constitutive JAK3 activity and IL-2–independent proliferation of NKTCL cells. JAK3A572V mutation causes constitutive JAK3 activity.

CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.

The effects of the FASN blocker C75 on cell growth and survival (A, E, and F), on expression/phosphorylation of PI3K and MAPK signaling proteins and on.

CDCP1 is required for invadopodia formation and ECM degradation by human breast cancer cells. CDCP1 is required for invadopodia formation and ECM degradation.

E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective breast tumors. E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective.

Silencing hOGG1 triggers caspase-3 and caspase-7 activation in response to H2O2 in GM00637 cells. Silencing hOGG1 triggers caspase-3 and caspase-7 activation.

Validation of the screen hits.

mTORC1 is required for malignant transformation in the Eμ-Myc model.

Antitumor activity of KM100+5 μmol/L MTX treatment in the presence or absence of CD8+ T cells in BALB-neuT mice bearing subcutaneous tumors of TUBO cells.

Mcl-1 knockdown promotes cleavage of caspase-3 in nonadherent melanoma cells. Mcl-1 knockdown promotes cleavage of caspase-3 in nonadherent melanoma cells.

Mitotic catastrophe symptoms caused by curcumin are followed by apoptosis. Mitotic catastrophe symptoms caused by curcumin are followed by apoptosis. A.

Sensor siRNAs can be used in high-order combinations.

A, TSG-6 staining in TRAMP tissue and TRAMP cell lines.

The effect of IAA and glycyrrhizin (Gc) on growth of human melanoma cells. The effect of IAA and glycyrrhizin (Gc) on growth of human melanoma cells. A,

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

IDO deficiency delays the development of pulmonary metastases.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

TFAP2A knockdown inhibits cell growth by targeting HIF-1α signaling.

Biological effects of BRAF silencing: growth curves of A375 (A) and ARO (B) cell lines in the absence or presence of doxycycline. Biological effects of.

Effect of IL24 on phosphorylation of eIF2α and proliferation in cancer cells. Effect of IL24 on phosphorylation of eIF2α and proliferation in cancer cells.

N-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. n-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. HEC-1-A.

Dual apoptotic signaling pathways triggered by IMMU-140: Anti–HLA-DR- and SN-38–mediated signals. Dual apoptotic signaling pathways triggered by IMMU-140:

CDCP1 links Ras and SFK signaling and regulates anoikis resistance, cell migration, and invasion in NSCLC cells. CDCP1 links Ras and SFK signaling and.

Endogenously produced n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in vivo. Endogenously produced n-3 PUFAs inhibit endometrial cancer.

KRAS mutation leads to resistance to combined RAF/EGFR and RAF/MEK inhibition. KRAS mutation leads to resistance to combined RAF/EGFR and RAF/MEK inhibition.

Effect of CDV on human SF7796 xenografts in vivo.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

The PI3Kβ inhibitor enhances the antitumor activity of T cell–mediated immunotherapy in mice bearing PTEN loss tumors. The PI3Kβ inhibitor enhances the.

Differential effects of the RAF inhibitor PLX4032 in BRAF-mutant melanoma, thyroid, and colorectal cancer cell lines. Differential effects of the RAF inhibitor.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

DEAR1 blocks TGF-β–induced anoikis resistance, and TGF-β and SMAD3 signal transduction. DEAR1 blocks TGF-β–induced anoikis resistance, and TGF-β and SMAD3.

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

Cabozantinib causes significant tumor cell elimination in vivo, but modest apoptosis induction in vitro. Cabozantinib causes significant tumor cell elimination.

LY elicits hyperphosphorylation of Akt.

Characterization of Lkb1-WT and Lkb1-null cell lines.

Elevated STAT3 phosphorylation and RANTES levels in tamoxifen-treated breast cancer cells. Elevated STAT3 phosphorylation and RANTES levels in tamoxifen-treated.

Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.

FGFR2 amplification in primary human gastric tumors predicts for response to NVP-BGJ398. FGFR2 amplification in primary human gastric tumors predicts for.

FGF19 amplification in liver cancer cell lines is associated with response to NVP-BGJ398. FGF19 amplification in liver cancer cell lines is associated.

BH3-targeted inhibitors drive specific resistance in human cell lines, which can be overcome with alternating or combining inhibitors. BH3-targeted inhibitors.

Effects of NMT siRNAs on MARCKS and c-Src.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

MET activation confers resistance to cetuximab (Cmab) or panitumumab (Pmab) in colon cancer cell lines in vitro and in vivo. MET activation confers resistance.

Wnt5A and ROR2 contribute to intrinsic resistance to BRAF inhibitors.

Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.

MITF-low/NF-κB–high transcriptional class is present and associated with resistance to MAPK pathway inhibition in human tumors. MITF-low/NF-κB–high transcriptional.

Presentation transcript:

TNFα is an important survival and growth signal for melanoma. TNFα is an important survival and growth signal for melanoma. A, the Kaplan–Meier plot showing melanoma-free survival (%) of tamoxifen-treated BrafV600E;Tyr::CreERT2 (BrafV600E) and BrafV600E;Tnfα−/−;Tyr::CreERT2 (BrafV600E/TNFα−/−) mice and control mice (ethanol-treated BrafV600E;Tnfα−/−;Tyr::CreERT2 mice and tamoxifen-treated Tyr::CreERT2 mice). P < 0.0001; log-rank (Mantel–Cox) test. B, growth of BrafV600E-4434 melanoma allografts in WT and TNFα−/− mice. C, in vitro growth assay of BrafV600E-4434 melanoma cells treated with BSA or 50 ng TNFα once every 3 days. D, anoikis assay of BrafV600E-4434 melanoma cells for dead cells detected by trypan blue staining. Cells were cultured under nonadherent conditions for 72 hours and treated with BSA or 50 ng TNFα. A Western blot for MITF, pIκBα, cleaved caspase-3, and ERK2 is shown. E, Western blot of the indicated cell lines for MITF and pIκBα and ERK2 after 24 hours of treatment with 50 ng TNFα. F, anoikis assay for untreated or TNFα-treated 4434, A375, and 4434-MITF– and A375-MITF–overexpressing cells. G, Western blot for MITF, pIκBα, cleaved caspase-3, and ERK2 of detached A375 and A375-MITF cells treated for 48 hours with 50 ng TNFα. H, anoikis assay for untreated or TNFα-stimulated A375 cells transfected with control or MITF-specific siRNAs. A Western blot for MITF, pIκBα, cleaved caspase-3, and ERK2 is shown. Michael P. Smith et al. Cancer Discovery 2014;4:1214-1229 ©2014 by American Association for Cancer Research